-

Bruce Booth is a Partner at Atlas Venture focused on helping start and fund emerging biotech therapeutics companies. He's married to a wonderful woman and has three great kids. Active skier, runner, fly fisherman.
-
subscribe by email
twitter
- MRK $5B stock buyback. R there not better uses? Acq things like Instagram & Tumblr 2 improve R&D visualization & micro-blogging study repts? 15 hours ago
- That said, "First-time" venture financings of new biotech are down however, and this is a concern. Need more new startups. #cvforum13 4 days ago
- Panel at #cvforum13 says Biotech VC funding at 95 levels. Not true. Overall biotech VC roughly stable for decade, w/ quarterly variation. 4 days ago
Recent Posts
current comments
- Kizi on Change Starts at the Top: Imperative to Bring Biotech Voices to Pharma Boardrooms
- Friv 4 on Welcoming Amgen & Novartis As Partners In Atlas IX
- kizi friv on VC-backed Biotech Holding Periods: Tortoise or Hare?
- Friv 4 on Life Sciences: The Rodney Dangerfield of Venture Capital
- Observer on Welcoming Amgen & Novartis As Partners In Atlas IX
topics
- Atlas Venture (2)
- Biotech financing (10)
- Biotech investment themes (13)
- Biotech startup advice (8)
- Boston Cluster (7)
- Capital efficiency (13)
- Diagnostics (2)
- Exits IPOs M&As (29)
- General Venture Capital (25)
- New business models (14)
- Personalized Medicine (2)
- Pharma industry (23)
- Portfolio news (10)
- Translational research (3)
- Uncategorized (12)
- VC-backed Biotech Returns (33)
Monthly Archive
- May 2013 (3)
- April 2013 (2)
- March 2013 (4)
- February 2013 (1)
- January 2013 (3)
- December 2012 (3)
- November 2012 (4)
- October 2012 (3)
- September 2012 (4)
- August 2012 (3)
- July 2012 (3)
- June 2012 (4)
- May 2012 (3)
- April 2012 (2)
- March 2012 (3)
- February 2012 (3)
- January 2012 (6)
- December 2011 (4)
- November 2011 (4)
- October 2011 (3)
- September 2011 (4)
- August 2011 (3)
- July 2011 (4)
- June 2011 (4)
- May 2011 (5)
- April 2011 (8)
- March 2011 (10)
Monthly Archives: June 2011
SciCafe: Snapshots of four Hot Boston Labs
June 16, 2011
A great group of four researchers shared updates on their lab’s recent findings at this morning’s SciCafe in Boston. Cancer, autoimmunity, stem cells – lots of great science. For those that don’t know SciCafe, here’s the background: Nature Biotech’s
SmartCells, Smart Story: Lean Biotech, Large Return
June 13, 2011
Todd Zion, the founder of the adjustable insulin company, SmartCells, has done wonders for the Boston Life Science angel community – and reinvigorated their interest in funding therapeutics companies. It’s a great story and Todd deserves the attention he’s been
Contrave: Latest Casualty in the FDA’s War Against Obesity Drugs
June 9, 2011
Last week’s news about Orexigen’s Contrave obesity drug and its struggles with the FDA’s Division of Metabolic and Endocrinologic Products has left me puzzled. Obesity is such an enormous epidemic, one has to wonder why the FDA is taking such
AVEO: An early stage VC perspective
June 2, 2011
I heard AVEO Pharmaceuticals’ CEO Tuan Ha-Ngoc speak at Convergence last month and decided AVEO would be a superb company to profile as a way to highlight the triad we all dream of in biotech venture investing: great science, great



